As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(781)535-1428
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Cancer Type | Cell Lines |
Colon cancer | PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C, PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C, PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C, |
Lung cancer | PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu, |
Gastric cancer | PDXM-092Ga, PDXM-091Ga, |
Breast cancer | PDXM-201B, PDXM-202B, PDX-203B |
Liver cancer | PDXM-211Li, PDXM-212Li |
Pancreas cancer | PDXM-221Pa, PDXM-222Pa |
Bladder Cancer | PDXM-231U, PDXM-232U |
Lymphoma | PDXM-241Ly, PDXM-242Ly |
The PDX model, also as known as the patient-derived tumor xenograft (PDX) model, is constructed by directly transplanting tumor tissue from a patient into a severely immunodeficient mouse and allowing the tumor tissue to grow within the mouse.
No in vitro culture process is required to "screen" tumors
Maintains the original characteristics and heterogeneity of the tumors
Maintains the original characteristics and heterogeneity of the tumors
Preserves the original non-tumor stroma and microenvironment
Enables research on tumors derived from patients under various conditions.
• New drug development
In particular, patient screening and predictive biomarker studies in clinical trials of tumor immune-targeted drugs show that PDX efficacy evaluation results and clinical similarity reached 87% (CDX only 5%).
• Personalized Medicine:
PDX model can be used to conduct pharmacodynamic (PD) evaluation experiments for tumor patients, providing clinical drug references for personalized treatment.
• Molecular Marker development (Biomarker)
Drug reactions -- Molecular biological mechanisms